Going Against the Gr-ADA: Metformin Use in Prediabetes

**Activity Title:**

Jack Janosik, PharmD

PGY2 Ambulatory Care Pharmacy Resident

UPMC Presbyterian/Shadyside

**Speaker:**

**Objectives:**

1. **Identify the diagnostic criteria and incidence of prediabetes**
2. **Discuss current guidance surrounding treatment of prediabetes**
3. **Describe evidence assessing the effect of metformin in prediabetes**

**Presentation Abstract:**

Prediabetes is a disease that affects nearly 1 in 3 American adults. Lifestyle interventions focused on exercising and losing weight is the gold standard of treatment to lower patients’ blood sugar and reduce their risk of developing type 2 diabetes. From a pharmacologic standpoint, metformin has the most evidence supporting its use to prevent/delay the progression of prediabetes to type 2 diabetes. Metformin for prediabetes has been considered in guidelines since as early as 2005. However, with new evidence and updated guidelines, the clinical significance of metformin use in prediabetes remains to be in question. This presentation will review evidence assessing the effect of metformin prediabetes and if there is a benefit for its use in prediabetic patients.

**Test Questions:**

1. According to long-term studies, approximately how many patients with prediabetes will NOT progress to diabetes even after many years?

a. 15%

b. 25%

c. 40%

d. 60% - answer

2. Why is metformin used in prediabetes?

a. Treats elevated BG - answer

b. Lowers MI risk

c. Helps patients lose weight

d. A and B

e. All of the above

3. In which situation would you feel most comfortable recommending metformin for a prediabetic patient?

a. The patient has high ASCVD risk (>10 %)

b. The patient requests metformin - answer

c. You don’t feel that the patient can make necessary lifestyle adjustments

d. The patient is < 45 years of age

**Format:**

Live

Home study

Live and Home study

Webinar (Live)

2/8/2023

**Date of Live Activity:**

**Activity length (hr. or CEU): 1 hour**

Topic Designators – activities are related to:

If a CPE activity’s target audience is exclusively for pharmacists, the designation “P” will be used as follows:

01-P Disease State Management/Drug therapy

02-P AIDS therapy

03-P Law (related to pharmacy practice)

04-P General Pharmacy

05-P Patient Safety

06-P Immunizations

07-P Compounding

08-P Pain Management/Opioids

**References:**

1. Centers for Disease Control and Prevention. Prediabetes – Your Chance to Prevent Type 2 Diabetes. Accessed December 12, 2022.
2. American Diabetes Association. Standards of Medical Care in Diabetes. *Diabetes Care*. 2005;28(suppl\_1):s4-s36.
3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. *Phys Ther*. 2008;88(11):1254-1264.
4. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: *Standards of Care in Diabetes—2023*. *Diabetes Care*. 2023;46(Supplement\_1):S19-S40.
5. ElSayed NA, Aleppo G, Aroda VR, et al. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: *Standards of Care in Diabetes—2023*. *Diabetes Care*. 2023;46(Supplement\_1):S41-S48.
6. ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic Targets: *Standards of Care in Diabetes—2023*. *Diabetes Care*. 2023;46(Supplement\_1):S97-S110.
7. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Care in Diabetes—2023*. *Diabetes Care*. 2023;46(Supplement\_1):S140-S157.
8. Davidson MB. Metformin Should Not Be Used to Treat Prediabetes. *Diabetes Care*. 2020;43(9):1983-1987.
9. Hughes A, Khan T, Kirley K, et al. Metformin Prescription Rates for Patients with Prediabetes. *J Am Board Fam Med*. 2022;35(4):821-826.
10. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *N Engl J Med*. 2002;346(6):393-403.
11. Diabetes Prevention Program Research Group, Nathan DM, Knowler WC, et al. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. *Diabetes Care*. 2019;42(4):601-608.
12. Davidson MB, Kahn RA. A Reappraisal of Prediabetes. *The Journal of Clinical Endocrinology & Metabolism*. 2016;101(7):2628-2635.
13. Vistisen D, Witte DR, Brunner EJ, et al. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. *Diabetes Care*. 2018;41(4):899-906.
14. Bancks MP, Ning H, Allen NB, et al. Long-term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level. *Diabetes Care*. 2019;42(3):457-465.
15. Kiviniemi AM, Lepojärvi ES, Tulppo MP, et al. Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study. *Diabetes Care*. 2019;42(7):1319-1325.
16. Echouffo-Tcheugui JB, Niiranen TJ, McCabe EL, et al. Lifetime Prevalence and Prognosis of Prediabetes Without Progression to Diabetes. *Diabetes Care*. 2018;41(7):e117-e118.
17. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N Engl J Med*. 1993;329(14):977-986.
18. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2018.
19. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;326(8):736.
20. van Herpt TTW, Ligthart S, Leening MJG, et al. Lifetime risk to progress from pre-diabetes to type 2 diabetes among women and men: comparison between American Diabetes Association and World Health Organization diagnostic criteria. *BMJ Open Diab Res Care*. 2020;8(2):e001529.